Open Access Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study
Published: 4 Apr 2005

Marcel Flendrie firstname.lastname@example.com
Department of Rheumatology
Radboud University Nijmegen Medical Centre
Nijmegenthe Netherlands

Wynand Hpm Vissers
Department of Dermatology
Radboud University Nijmegen Medical Centre
Nijmegenthe Netherlands

Marjonne Cw Creemers
Department of Rheumatology
Radboud University Nijmegen Medical Centre
Nijmegenthe Netherlands

Elke Mgj De Jong
Department of Dermatology
Radboud University Nijmegen Medical Centre
Nijmegenthe Netherlands

Peter Cm Van De Kerkhof
Department of Dermatology
Radboud University Nijmegen Medical Centre
Nijmegenthe Netherlands

Piet Lcm Van Riel
Department of Rheumatology
Radboud University Nijmegen Medical Centre
Nijmegenthe Netherlands

Open Access Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study
Published: 4 Apr 200510.1186/ar1724)Received: 3 Jan 2005 Revisions requested: 20 Jan 2005 Revisions received: 25 Feb 2005 Accepted: 1 Mar 2005Available online Research article
Various dermatological conditions have been reported during tumor necrosis factor (TNF)-α-blocking therapy, but until now no prospective studies have been focused on this aspect. The present study was set up to investigate the number and nature of clinically important dermatological conditions during TNF-αblocking therapy in patients with rheumatoid arthritis (RA). RA patients starting on TNF-α-blocking therapy were prospectively followed up. The numbers and natures of dermatological events giving rise to a dermatological consultation were recorded. The patients with a dermatological event were compared with a group of prospectively followed up RA control patients, naive to TNF-α-blocking therapy and matched for follow-up period. 289 RA patients started TNF-α-blocking therapy. 128 dermatological events were recorded in 72 patients (25%) during 911 patient-years of follow-up. TNF-α-blocking therapy was stopped in 19 (26%) of these 72 patients because of the dermatological event. More of the RA patients given TNF-αblocking therapy (25%) than of the anti-TNF-α-naive patients (13%) visited a dermatologist during follow-up (P < 0.0005). Events were recorded more often during active treatment (0.16 events per patient-year) than during the period of withdrawal of TNF-α-blocking therapy (0.09 events per patient-year, P < 0.0005). The events recorded most frequently were skin infections (n = 33), eczema (n = 20), and drug-related eruptions (n = 15). Other events with a possible relation to TNF-αblocking therapy included vasculitis, psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid-papulosis-like eruption. This study is the first large prospective study focusing on dermatological conditions during TNF-α-blocking therapy. It shows that dermatological conditions are a significant and clinically important problem in RA patients receiving TNF-α-blocking therapy. CI = confidence interval; DAS28 = disease activity score including 28-joint counts; DMARD = disease-modifying antirheumatic drug; ELISA = enzyme-linked immunosorbent assay; pt-yr = patient-year; RA = rheumatoid arthritis; Th1/Th2 = T helper cell type 1/2; TNF = tumor necrosis factor.Arthritis Research & TherapyVol 7 No 3 Flendrie et al.R667as biological registries are needed to provide information on the nature and number of such dermatological adverse events during TNF-α-blocking therapy.

Introduction

The introduction of biological agents such as TNF-α-blocking agents has dramatically changed the therapeutic approach to rheumatic diseases in recent years. TNF-α-blocking therapy has had a remarkable effect on disease activity in an increasing number of rheumatic diseases, including rheumatoid arthritis (RA) [1][2][3], juvenile idiopathic arthritis [4], ankylosing spondylitis [5,6], and psoriatic arthritis [7]. At present, two monoclonal anti-TNF-α antibodies (infliximab and adalimumab) and one soluble p75 TNF-α receptor (etanercept) are being used in rheumatological practice.

Various skin conditions have been reported in clinical trials, including urticaria, rash, and stomatitis (during infliximab therapy) [8]; rash and injection-site reactions (during adalimumab therapy) [3,9]; and injection-site reactions (during etanercept therapy) [2].

However, clinical trials are not designed to provide information about the occurrence of rare adverse events associated with TNF-α-blocking therapy. More severe cutaneous reactions, such as erythema multiforme, discoid and subacute cutaneous lupus erythematosus, atopic dermatitis, necrotizing vasculitis, and bullous skin lesions, have been reported, mostly as singlecase observations [10][11][12][13][14][15]. Larger observational studies such The aim of this study was to investigate whether dermatological conditions after TNF-α-blocking therapy are a significant and clinically important problem in RA patients receiving TNFα-blocking therapy.

Materials and methods

Study design

In a prospective cohort study, all consecutive patients with a diagnosis of RA according to the criteria of the American Rheumatism Association [16] who were starting on TNF-αblocking therapy at the Department Of Rheumatology of the Radboud University Nijmegen Medical Centre were followed as part of a Biological Registry [17]. Approval was obtained by the hospital's ethics committee.

Patients were required to meet the criteria set out in the Dutch guidelines for biological therapies: a moderate to high disease activity score (DAS) based on 28 joints (DAS28 ≥ 3.2), and failure or intolerability of at least two disease-modifying antirheumatic drugs (DMARDs), including methotrexate, in adequate dosage regimens. Besides therapy with registrated TNF-α-blocking agents -infliximab, etanercept, and adalimumab -some patients were treated in clinical trials with lenercept, a soluble p55 TNF-α-receptor [18].

The number and nature of dermatological conditions that led patients in this cohort to consult a dermatologist during followup were investigated. The RA patients treated with TNA-αblocking agents who experienced dermatological events was compared with a control group of patients who had RA but had never had TNF-α-blocking therapy. The control patients were selected from the Nijmegen inception cohort, in which 500 RA patients have been followed since 1985 [19]. Each control was paired with a TNF-α-treated patient for duration and season of the follow-up period, within a 2-month window.

Variables

Data collected at the start of TNF-α-blocking therapy were age, sex, duration of disease, presence or absence of rheumatoid factor (measured by ELISA; considered positive if results showed >10 IU/ml), antinuclear antibody (tested for by immunofluorescence on Hep-2 cells), number of DMARDs previously used, and start date of TNF-α-blocking therapy. Baseline information obtained included erythrocyte sedimentation rate (ESR), 28-joint counts for swelling and tenderness, and general wellbeing as indicated on a visual analogue scale, and the disease activity score (DAS28) was calculated [20].

Variables about which information was collected during TNFα-blocking therapy were the use of concomitant DMARDs and prednisolone, dose and interval changes of TNF-α-blocking agents and, if appropriate, date and reason for discontinuation.

All patients who visited a dermatologist during follow-up were identified. Clinically important dermatological events were defined as any new manifestation or any exacerbation of preexisting skin disease during follow-up. A standardized chart review form was used to record the following: start date of event, dermatological history, medication, morphological description, localization, histopathological and immunohistological information if available, working diagnosis, additional investigations, topical and systemic therapeutic actions, outcome of event, and any available information on rechallenge.

Drug-related eruptions were defined as skin reactions with a probable or definite relation to the use of TNF-α-blocking agents, based on a time relation with the administration of the agent, morphological pattern, and/or histological information. Drug-related eruptions were classified morphologically according to the criteria of Fitzpatrick and colleagues [21]. Events were also classified as major or minor, major events being any requiring hospitalization.

Patient-years of follow-up were calculated for total follow-up, time on active therapy, and time after discontinuation of therapy (time off therapy). The number of events per year of followup was calculated for each RA patient for total time of followup, time on active treatment, and time off treatment, if appropriate.

In the control group, the following baseline characteristics were collected: age, sex, disease duration, rheumatoid factor, antinuclear antibody, DAS28, the number of DMARDs previously used, and prednisolone use. All visits to a dermatologist during follow-up were identified. Events were not recorded in the control group.

Statistical analyses

The baseline characteristics of RA patients on TNF-α-blocking therapy were compared according to whether or not the patients experienced dermatological events. The chi-square test was applied for dichotomous variables and Student's ttest was used for continuous variables. Nonparametric tests were applied when appropriate. The Wilcoxon signed rank test was used to compare the number of events per patient-year of follow-up in patients receiving and patients not receiving active TNF-α-blocking therapy. Univariate and multivariate logistic regression analyses were performed to identify possible predictive factors for the occurrence of a dermatological visit (independent variable, dichotomous) in RA patients on TNF-α-blocking therapy. Dependent variables tested were sex, age at diagnosis, rheumatoid factor, antinuclear antibody, disease duration, DAS28 at baseline, prior number of DMARDs, use of prednisolone, and duration of follow-up.

Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.

The number of patients who visited a dermatologist was compared between RA patients on TNF-α-blocking therapy and controls, using the chi-square test. P values and ORs were calculated.

All tests were two-sided, with P < 0.05 considered statistically significant. Statistical analyses were performed using SPSS statistical software (v 12.0.1, SPSS Inc, USA).

Results

Patients

A total of 289 RA patients started TNF-α-blocking therapy between June 1994 and December 2003. Their baseline characteristics are shown in Table 1.

The median follow-up time was 2.3 years (range 0.02 to 9.6). The total follow-up time was 911 patient-years, with 627 patient-years representing active therapy. Seventy of the 289 RA patients (24%) received more than one TNF-α-blocking agent and 8 (3%) received more than two agents. Infliximab was administered to 167 patients, adalimumab to 108, etanercept to 78, and lenercept to 31.

Dermatological events were recorded in 72 of the 289 RA patients (25%) receiving TNF-α-blocking therapy and in 37 (13%) of the control group (n = 289). The odds ratio (OR) of TNF-α-blocking therapy for a dermatological referral was 2.26 (95%CI 1.46 to 3.50, P < 0.0005). In patients on TNF-αblocking therapy fifty-six instances of dermatological conditions were recorded in 34 patients (47%) and included, among others, 10 drug reactions -while the patient was receiving gold (7), nonsteroidal anti-inflammatory drugs (2), or methotrexate (1) -10 cases of eczema, 9 of mycosis, 3 of other infections, and 5 of chronic venous insufficiency.

Predictive factors

In univariate analyses, duration of follow-up (OR 1.27, 95%CI 1.14 to 1.41, P < 0.0005) and of disease (OR 1.03, 95%CI 1.003 to 1.07, P < 0.05) were statistically significant predictive factors for a dermatological event. In a multivariate model, only duration of follow-up was a statistically significant predictive factor (OR 1.30, 95%CI 1.12 to 1.52, P < 0.001).

Dermatological events

One hundred and twenty-eight dermatological events were recorded during follow-up in RA patients on TNF-α-blocking therapy (0.14 event per patient-year), as listed in Table 2. The event per patient-year ratio was 0.16 during active treatment and 0.10 off treatment (P < 0.001). The number of events recorded during or after treatment was 56 for adalimumab (0.12 event per patient-year), 49 for infliximab (0.14 per patient-year), 16 for etanercept (0.13 per patient-year), and 13 for lenercept (0.07 per patient-year). TNF-α-blocking therapy was permanently withdrawn because of dermatological events 21 times in 19 patients.

Infections

Thirty-three infections were recorded in 27 patients, consisting of 20 fungal, 11 bacterial, and 2 viral infections (see Table  3). Two patients had had a previous episode of dermatomycosis. None of the patients required hospitalization. One patient, who temporarily discontinued adalimumab monotherapy twice because of elective surgery, developed a bacterial superinfection of pre-existing eczema after every restart. Table 1 Baseline characteristics of patients with rheumatoid arthritis (RA) studied  (7)** a Not given TNF-α-blocking therapy. b ANA at start was present in respectively 261 and 67 patients on TNF-α-blocking therapy. *P < 0.001, **P < 0.0001, compared with RA patients on TNF-α-blocking therapy; † P < 0.001 compared with RA patients on TNF-α-blocking therapy who experienced no dermatological events. ANA, antinuclear antibody; DAS28, disease activity score based on 28 joints; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor; SD, standard deviation; TNF, tumor necrosis factor.

Eczema

Eczema was diagnosed 20 times in 19 patients and appeared in various morphological patterns. Most events were described as erythematosquamous (n = 8) or erythematous (n = 3) lesions or plaques, localized on hands and feet (n = 3), arms and legs (n = 5), face (n = 1), neck (n = 1), and buttocks (n = 1). A vesicular rash on hands and feet was described five times. A papular rash was described in three cases, with localization around the eyes, on the back, and once on the back and lower legs. Diagnoses comprised dyshidrotic (n = 5), contact (n = 4), nummular (n = 1), atopic (n = 1), papular (n = 1), and nonspecific eczema (n = 8). Two patients had a prior history of dyshidrotic eczema.

Biopsies were performed in five events. Histology showed dermatitis and spongiosis in all cases, with high dermal perivascular infiltration in three. One biopsy also showed mild psoriasiform acanthosis and another showed additional keratinocyte necrosis.

Three patients stopped TNF-α-blocking therapy because of the dermatological event, after which the lesions resolved. Hospitalization was necessary for treatment of eczema in one patient. In another patient the eczematous lesions recurred after adalimumab therapy was restarted. Adalimumab was continued and topical steroids were applied with good effect. TNF-α-blocking therapy had already been stopped in 4 patients before the onset of eczema and was continued in 13 patients, of whom 7 had persisting or recurring lesions. Therapy consisted mostly of topical corticosteroids.

Drug-related eruptions

Drug-related eruptions occurred frequently during the first 5 months of TNF-α-blocking therapy and were caused by all four TNF-α-blocking agents (see Table 4). In two cases, a generalized drug-related eruption followed subcutaneous injection of etanercept. In two cases, the eruption developed during infusion (patients numbers 8 and 11, Table 4). In the other cases the time of onset ranged between 2 and 57 days after the most recent infusion.

Most drug-related eruptions consisted of a combination of morphological patterns, including exanthema, urticarial eruptions, lichenoid skin lesions, and purpura. In four patients, an eczematous drug-related eruption was seen. Classification as drug-related eruption was based on a time relation with administration of the TNF-α-blocking agent, the morphological pattern, and/or histological information. Two patients had experienced a previous drug-induced eruption (1 dermatitis in response to gold, 1 dermatitis after indomethacin).

The histological findings were compatible with the diagnosis in all cases. Perivascular infiltrations -predominantly lymphocytic -epidermal exocytosis, and hyperorthokeratosis were described. Interface dermatitis was described in three instances. One biopsy revealed focal infiltrations with marked vascular and endothelial proliferation.

Seven patients stopped and 8 patients continued therapy; 6 of them had a positive rechallenge and recurring lesions. One major event was recorded: an RA patient was hospitalized for an extensive eczematous eruption with urticaria on arms and legs (Fig. 1, and Patient no. 6 in Table 4). Treatment consisted mostly of topical application of corticosteroids and sometimes of systemic antihistamines.

Tumors and actinic keratosis

Events of skin malignancies were recorded five times, in four patients. One RA patient developed three basal cell carcinomas simultaneously on her left arm, right nostril, and right eyelid after 2.7 years of adalimumab therapy, which was subsequently stopped. One 74-year-old RA patient developed Bowen's disease on his right hand 2 years after adalimumab therapy had been stopped. The same patient later developed a squamous cell carcinoma on the left earlobe after the start of etanercept therapy. Other skin malignancies recorded were a squamous cell carcinoma (earlobe) after 1.5 months of adalimumab therapy and a low-grade basalioma (Pinkus epithelioma) on the leg after 6 months of adalimumab therapy. In all cases, histology confirmed the diagnosis and therapy consisted of excision. No recurrences were seen.

Actinic keratosis was recorded in five patients (three receiving adalimumab, one infliximab, and one lenercept). Excision or cryotherapy was successful in four. One patient had recurring actinic lesions on the scalp.

Benign tumors were recorded seven times during TNF-αblocking therapy. One patient experienced an increased growth of a facial telangiectatic nevus, present since childhood, 2 months after starting etanercept therapy. Seborrheic keratosis (n = 3), oral hyperkeratosis (n = 1), histiocytoma (n = 1), and fibroma (n = 1) were also recorded.

Vasculitis

Vasculitis was recorded five times: four during and one after cessation of TNF-α-blocking therapy. The diagnosis was confirmed by biopsy in four cases. One patient developed a superficial necrotizing leukocytoclastic vasculitis with ulceration after 7 months of infliximab therapy, with complete recovery after discontinuation of infliximab. One patient developed a papular erythema in the groins after 5 years of adalimumab therapy. Histological examination was compatible with vasculitis with infiltration of mononuclear cells and presence of eosi-  after one year of adalimumab therapy, which was continued. The lesions persisted. No biopsy was performed. One patient developed a generalized urticarial exanthema after therapy with etanercept 2 years earlier. Current therapy consisted of hydroxychloroquine and prednisolone. Histology showed a mild leukocytoclastic vasculitis.

Ulcers

The nine events with ulcers included four pressure ulcers, two ulcers due to dependency edema, one traumatic ulcer, one ulcer secondary to an unguis incarnatus, and one ulcer without further specification. Biopsies were taken in two patients, but no signs of vasculitis were found. A patient had a pressure ulcer with secondary infection and a fistula on his ankle, which contained osteosynthetic material. The patient was admitted to the hospital for intravenous antibiotic therapy and infliximab was stopped for several months. After recovery, the patient restarted infliximab without recurrence of his skin problems. TNF-α-blocking therapy was continued in the other eight patients, and in four of these the ulcers recovered; follow-up was missing in the other four.

Stasis dermatitis, edema, varices and chronic venous insufficiency

In 10 patients, a dermatological consultation was recorded for stasis dermatitis (n = 3), edema (n = 3), varices (n = 2), or chronic venous insufficiency (n = 2). In one patient with extensive varices, infliximab therapy was stopped temporarily because of a complicating thrombophlebitis. One patient had edema of both legs of unknown cause, with livid discoloration and induration. One patient had lymphedema secondary to RA. All other events were considered to be related to comorbidity, other than RA.

Psoriasis and psoriasiform eruptions

Psoriatic or psoriasiform eruptions were recorded in three RA patients. One developed a vesiculopustular erythematosquamous rash on hands and feet after 9 months of adalimumab therapy. Histology showed a mixed psoriasiform and spongiotic dermatitis. A second RA patient developed psoriasis guttata-like eruptions on her lower legs after 4 years of therapy with adalimumab. The lesions diminished after adalimumab was withdrawn. A third patient developed a psoriasiform eruption on arms and legs after 16 months of adalimumab therapy. Histology obtained in the latter two patients was consistent with psoriasis.

Other dermatological conditions

Other dermatological conditions that occurred during or after TNF-α-blocking therapy included, among others, dermatomyositis (1), drug-induced systemic lupus erythematosus (1), and lymphomatoid papulosis-like eruption (1). Details are shown in Table 5.

One RA patient developed a macular rash on the inner sides of the upper arms and legs after 2.5 months of lenercept monotherapy. A skin biopsy showed a nonspecific chronic dermatitis. A soft-tissue biopsy, including skin, fascia, and muscle, showed fascial and muscular infiltration, consistent with dermatomyositis. One RA patient developed a drug-induced systemic lupus erythematosus after 20 months of infliximab therapy in combination with methotrexate, consisting of discoid lupus erythematosus lesions on her hands and scalp, aphthous lesions, conversion to antinuclear antibody positivity, and a positive anti-double stranded-DNA (titer 60 U/L). The skin lesions flared within one week after infusion and disappeared after discontinuation of infliximab.

A third RA patient developed macular erythematosquamous lesions on her lower arms, upper legs and trunk after 2.6 months of adalimumab monotherapy. Histology showed a dermal infiltration with CD30-positive atypical T cells. Although the lesions appeared to be lymphomatoid papulosis, they completely disappeared within 6 weeks. Adalimumab was not stopped. This patient developed a large-cell anaplastic non-Hodgkin lymphoma 2 years later.

Discussion

The present study is the first large prospective study focusing on dermatological conditions in RA patients on TNF-α-block-ing therapy. Of the patients studied, 25% needed a dermatological consultation, compared with 13% in a RA control group, naive to TNF-α-blocking therapy. The number of dermatological events per patient-year was significantly higher during treatment than after treatment with TNF-α-blocking therapy. Dermatological events led to withdrawal of TNF-αblocking therapy in 19 patients of 72 patients (26%). The events recorded most frequently were skin infections, eczema, and drug-related eruptions. Some other interesting events were recorded, such as psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoidpapulosis like eruption.

RA is known to be associated with dermatological conditions such as vasculitis, nodulosis, palmar erythema, and bullous pemphigoid, among others [22,23]. At present, information on the incidence and prevalence of dermatological conditions in RA mainly originates from cross-sectional or retrospective studies [24][25][26]. Few prospective studies have been conducted focusing on specific conditions affecting the skin [27,28]. In establishing a relation between the use of a drug and the occurrence of dermatological conditions, various factors must be considered. Information on clinical and histological patterns, time and dose relation, dechallenge and rechallenge, and analogy with previously reported cases can provide support in assessing the plausibility of such a relation [29]. The underlying disease and concomitant medication also need careful consideration, as they can provide alternative explanations.

In this study the largest group of dermatological events consisted of skin infections, mostly fungal infections and folliculitis. The use of TNF-α-blocking therapy has raised concerns regarding an increased susceptibility to infections, as TNF-α plays an important role in host-defence mechanisms [30]. An increased incidence of tuberculosis has been described [31], as well as a growing number of serious infections with fungal, mycobacterial, and intracellular bacterial pathogens [32][33][34].

Infections of the skin have not been the subject of report in clinical trials and observational studies with TNF-α-blocking therapy. Cases of severe necrotizing fasciitis have been described [35,36].

Skin infections have been reported frequently in the normal population and especially in RA patients [24][25][26]. Hostdefence impairments resulting from the underlying disease might play a role in an increased susceptibility to skin infections in RA patients, as well as the use of corticosteroids and DMARDs such as methotrexate [28,37], which were recorded frequently in the present study (see Table 2). They could provide an alternative explanation for the occurrence of skin infections. However, most infections occurred during active treatment with TNF-α-blocking therapy, a finding that could suggest at least a relative contribution to an increased vulnerability to skin infections in the study population. In one patient, a bacterial superinfection of eczema occurred twice immediately after restart of adalimumab, showing a clear time relation.

For the description of the recorded drug-related eruptions, a clinico-morphological classification was chosen [21]. Four eruptions with a time relation and clinically or histological distinct drug-induced patterns also showed an eczematous appearance, both clinically and histologically. This is an unusual presentation for a drug-induced eruption and warrants further investigation.

Two drug-related eruptions occurred during infusion with infliximab or adalimumab, whereas all the others occurred after infusion. This will most likely not reflect the true ratio between acute and delayed reactions involving the skin, since acute reactions with skin involvement occur in 4% of the infusions and are usually treated by the rheumatologist without dermatological consultation [38].

Eczema was reported frequently in this study, even with various dermatitis conditions, such as xerosis cutis, stasis eczema, and seborrheic eczema, classified as separate entities. Previous studies have reported RA, in which Th1 (T helper cell type 1) immune responses dominate, to be negatively associated with Th2-cell-mediated atopic disorders, such as eczema [39][40][41], although a similar incidence of eczema in RA and non-RA patients has also been reported [42]. TNF-αblocking therapy down-regulates Th1 immune responses [43], which might induce a shift of the Th1/Th2 balance towards Th2-dominated immune responses and which might promote an increased susceptibility to atopic disorders, such as eczema.

Although the time between the initiation of TNF-α-blocking therapy and the onset of dermatological conditions varied, a probable relation was seen in various events. These included, besides drug-related eruptions, events of cutaneous vasculitis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid papulosis-like eruption.

An association between the use of TNF-α-blocking therapy and the induction of systemic lupus erythematosus and discoid lupus erythematosus is strongly suggested by the number of cases that have been published [10,11,13,[44][45][46]. One case of discoid lupus erythematosus has been described on both etanercept and infliximab in the same RA patient [47].

Analogy with previous reports is also present for cutaneous vasculitis [13,[47][48][49], although it is a known extra-articular manifestation of RA [22,23]. In the first case described, a probable relation with infliximab was present, based on the time relation and positive dechallenge. The other cases described were considered possibly related (Results section, Vaculitis, cases 2 and 3) and unlikely (cases 4 and 5). Almost all reported ulcers were considered secondary to other causes, as described.

Dermatomyositis has been reported previously, although the patient affected in that case had a different presentation, with raised creatinine phosphokinase, muscle atrophy, mechanic's hands, and vasculitis [17].

Another interesting finding was the occurrence of psoriasiform eruptions in three patients on TNF-α-blocking therapy. This observation is particularly interesting, since etanercept has received and infliximab is close to receiving FDA approval for treatment of psoriasis, after remarkable efficacy results in clinical trials [7,50,51]. The occurrence of guttate psoriasis has been reported after initiation of etanercept therapy for psoriasis in a placebo-controlled trial [51]. Another case report described the occurrence of psoriasiform eruptions with histologically a lichenoid dermatitis pattern in a patient with Crohn's disease [52].

An exacerbation of psoriasis was also seen in a patient with psoriatic arthritis receiving infliximab therapy. An additional analysis showed that 28 patients with various non-RA rheumatic diseases, including 12 juvenile idiopathic arthritis, 6 psoriatic arthritis, and 3 ankylosing spondylitis, had been treated with TNF-α-blocking therapy in the study centre. Five patients (18%) had visited a dermatologist for a dermatological condition during or after TNF-α-blocking therapy. The events included a drug-related eruption, eczema, and a facial mycosis in three patients with juvenile idiopathic arthritis and a superficial spreading melanoma in a patient with ankylosing spondylitis. This indicates that the occurrence of dermatological events during TNF-α-blocking therapy is not restricted to RA patients.

In the present study the control patients were matched for sartdate and duration of follow-up period in order to control for time-related effects. A statistically significant relation between the use of TNF-α-blocking therapy and the occurrence of dermatological visits was shown. The two groups studied differed for most baseline characteristics. These differences result from the indication for TNF-α-blocking agents, which were reserved for patients who fulfilled criteria for active disease and DMARD failure (see methods section; study design), had a longer disease duration, and whose disease was perhaps more refractory.

However, it is considered unlikely that these factors influenced the relation between the use of TNF-α-blocking therapy and dermatological visits. In a multivariate regression model, no baseline characteristic showed a predictive value for the occurrence of a dermatological event in RA patients on TNFα-blocking therapy. Also, a statistically significantly higher number of dermatological events was recorded during active treatment with TNF-α-blocking therapy than after the therapy had been stopped.

Conclusion

This is the first prospective study showing a relation between TNF-α-blocking therapy and the occurrence of dermatological conditions. Future prospective studies are needed to investigate the incidence and the pathogenesis of the encountered events, because they are a clinically significant problem in RA patients receiving TNF-α-blocking therapy.

Figure 1
1Eczematous drug-related eruption a patient with rheumatoid arthritis after infliximab therapy: Eczematous eruptions on the left arm (top left) and right arm (top right) and erythematous eruptions with purpura on the left leg (bottom left) and right leg (bottom right) Eczematous drug-related eruption a patient with rheumatoid arthritis after infliximab therapy: Eczematous eruptions on the left arm (top left) and right arm (top right) and erythematous eruptions with purpura on the left leg (bottom left) and right leg (bottom right).

Table 2
2Dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy Median and range given for three cases or more; individual data given for two cases or fewer. b Number of patients with concomitant DMARDs and prednisolone at the time of event. c Permanent discontinuation of TNF-α-blocking therapy because of the event. DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor.Nature of event
Events
Time to event (months)
Events during
treatment

Major events
Histology
DMARDs b
Prednisolone b
Permanent
withdrawal of anti-
TNF-α c

No. (%)
Median a
Range
No. (%)
No. (%)
No. (%)
No. (%)
No. (%)
No. (%)

Infection
33 (25.8)
9.1
1.1-61.1
24 (73)
0
5 (15)
20 (61)
21 (64)
4 (12)

Eczema
20 (15.6)
7.1
0.2-49.9
16 (80)
1 (5)
4 (20)
8 (40)
7 (35)
3 (15)

Drug-related eruption 15 (11.7)
1.9
0.1-18.8
15 (100)
1 (7)
12 (80)
6 (40)
6 (40)
7 47)

Ulcers
9 (7.0)
13.6
0.3-52.5
3 (33)
1 (11)
2 (22)
7 (78)
4 (44)
1 (11)

Skin tumor, benign
7 (5.5)
12.9
2.0-18.1
7 (100)
0
2 (29)
5 (71)
4 (57)
0

Skin tumor, malignant
5 (3.9)
4.5
1.1-38.0
4 (80)
0
5 (100)
2 (40)
2 (40)
1 (20)

Xerosis cutis
6 (4.7)
8.9
4.2-26.3
6 (100)
0
1 (16)
4 (67)
1 (17)
1 (17)

Vasculitis
5 (3.9)
12.0
1.5-49.9
4 (80)
0
4 (80)
3 (60)
5 (100)
1 (20)

Actinic keratosis
5 (3.9)
26.3
4.5-112.9
2 (40)
0
3 (60)
5 (100)
2 (40)
0

CVI/varices
4 (3.0)
24.0
1.7-33.6
3 (75)
0
0
3 (75)
2 (50)
0

Psoriasis/
psoriasiform

3 (2.3)
15.5
8.4-50.1
3 (100)
0
3 (100)
0
2 (67)
1 (33)

Edema
3 (2.2)
8.2
4.0-39.6
2 (67)
0
1 (33)
1 (33)
1 (33)
0

Stasis dermatitis
3 (2.2)
17.5
14.6-42.1
3 (100)
0
1 (33)
1 (33)
1 (33)
0

Seborrheic dermatitis
2 (1.5)
0.4, 19.8
-
2 (100)
0
0
0
0
0

Other event
8 (6.0)
5.0
1.9-25.9
6 (75)
0
4 (50)
4 (50)
2 (25)
2 (25)

Total
128 (100)
9.1
0.1-112.9
100 (78)
3 (2)
47 (37)
69 (54)
60 (47)
21 (16)

a

Table 3
3Skin infections in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapya A, adalimumab; I, infliximab; E, etanercept; L, lenercept. b During active treatment with TNF-α-blocking therapy. c Permanent discontinuation of TNFα-blocking therapy due to the event. d Individual valuesTime to event

Infection
No. of events
Median
Range
Drug a (no.) Active treatment b
(no.)

Rechallenge
(no.)

Permanent
withdrawal of anti-
TNF-α c (no.)

Biopsy
(no.)

Cultured species

Fungal
20
8.7
1.1-61.1

Dermatomycosis
9
A 3, I 4, E 2
7
0
1
Trichophyton
verrucosum (1) T.
rubrum (1)

Onychomycosis
3
A 3
3
0
0

Combination
5
A 3, I 1, L 1
4
0
1
Trichophyton
rubrum (3) T.
mentagrofytes (1)

Candidiasis
3
I 3
2
0
0
Candida spp. (2)

Bacterial
11
9.5
1.4-52.5

Folliculitis
5
A 3, E 2
4
yes, negative
1
2
Staphylococcus
aureus (1)

Erysipelas
3
E 2, I 1
3
yes, negative
2
1

Bacterial
superinfection of
eczema

2
A 1, I 1
1
yes, positive
1
0

Furuncle
1
I 1
0
0
0

Viral -herpes zoster
2
17.3, 40.9 d
A 1, I 1
0
0
0

Table 4
4Drug-related skin eruptions in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapyPatient
no.

Age
(yr)

Sex Drug a Route Type of eruption Clinical
description

Localization Time to
event
(mo)

Biopsy Comedication b
Therapy
Rechallenge Permanent
withdrawal
of anti-
TNF-α

Course

1
62
f
A
i.v. Eczematous
Erythematosq
uamous
plaques and
papules

Neck/
axillary/
legs

4.5
Yes naproxen
Local
positive
No
Recurring

2
71
m
A
i.v. Exanthematous
lichenoid

Maculopapula
r exanthema

Generalized
0.7
Yes prednisolone,
naproxen,
paracetamol

Local
positive
Yes
Recovery

3
77
m
E
s.c. Exanthematous Macular
exanthema

Generalized
6.8
Yes prednisolone,
naproxen,
omeprazole

Local
positive
No
Recurring

4
67
m
E
s.c. Lichenoid
Macular
exanthema,
purpura

Generalized
1.5
Yes diclofenac,
omeprazole,
triamterene,
furosemide,
candesartan

Topical,
systemic

No
Yes
Recovery

5
69
f
I
i.v. Eczematous
Erythematous
plaque

Right cheek
0.1
Yes MTX, pantoprazole,
atenolol, calcium,
hydrochlorothiazi
de

Topical
positive
No
Recurring

6
88
f
I
i.v. Eczematous
urticarial

Erythematosq
uamous
macula,
purpura

Lower
arms/legs

3.9
Yes leflunomide,
carbasalate
calcium,
omeprazole,
furosemide,
simvastatin,
paracetamol

Topical
No
Yes
Recovery

7
68
f
I
i.v. Eczematous
urticarial

Erythematosq
uamous
plaques,
urticaria,
excoriations,
lichenificatio
n, purpura

Generalized 10.3
No AZA, furosemide,
oxazepam,
enalapril,
spironolactone,
metoprolol,
flixotide,
formoterol

Topical,
systemic

negative
No
Recovery

8
60
f
I
i.v. Exanthematous Stippled
exanthema

Generalized
0.5
Yes naproxen,
omeprazole

Topical
No
Yes
Recovery

9
53
f
I
i.v. Exanthematous Exanthema
Upper
arms/legs

0.2
No indomethacin
Topical
positive
No
Recurring

10
73
f
I
i.v. Exanthematous,
with purpura

Exanthema,
purpura

Lower legs
18.8
No MTX, folic acid,
prednisolone,
morphine,
loperamide,
latanoprost

Topical
No
Yes
Recovery

11
70
f
I
i.v. Exanthematous
urticarial

Exanthema,
urticaria

Arms/ trunk
16.6
Yes leflunomide
None
positive
No
Recurring

12
35
f
I
i.v. Exanthematous
urticarial, with
purpura

Macular
exanthema,
uricaria,
purpura

Trunk/
axillary/
groins

1.9
Yes none
Topical
-
Yes
Recovery

13
58
f
I
i.v. Lichenoid
Erythema,
hyperpigme
ntation,
atrophy

Upper legs
15.5
Yes leflunomide,
meloxicam,
metoclopramide,
acenocoumarol,
digoxin

None
No
Yes
Recovery

14
58
f
L
i.v. Exanthematous Papular
exanthema

Generalized
0.4
Yes none
Topical
positive
No
Recurring

15
68
m
L
i.v. Exanthematous
lichenoid

Maculopapula
r exanthema

Generalized
1.7
Yes prednisolone,
paracetamol

Topical
negative
No
Recovery

Events numbers 5 and 11 occurred in the same patient, as did events numbers 2, 3, and 15. a A, adalimumab; Age = age ar event; I, infliximab; E,
etanercept; L, lenercept. b MTX, methotrexate; AZA, azathioprine. f, female; i.v., intravenous; m, male; s.c., subcutaneous.

Table 5
5Other dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapyPatient
no.

Age (yr) Sex Diagnosis Drug a Active
treatment

Event
Clinical
description

Localization Time to
event

Biopsy Comedication b Permanent
withdrawal
anti-TNF-α

Therapy
Course

1
56
f
RA
A
Yes
Lymphomatoid
papulosis-
like eruption

Macular
erythematos
quamous
lesions

Lower
arms,
upper
legs and
trunk

2.6
Yes naproxen
No
None
Recovery

2
53
f
RA
A
Yes
Rosacea
Diffuse
erythema,
scaling,
telangiectasi
as

Head and
face

1.9
Yes prednisolone,
captopril,
indomethaci
n, midazolam

No
Topical
Persisting

3
74
f
RA
E
Yes
Pruritus
Itch
Trunk
2.5
No None
No
Topical
Unknown

4
61
f
RA
I
No
Ecchymoses Ecchymoses Hands and
feet

25.9
No AZA,
prednisolone

No
Topical
Partial
recovery

5
58
f
RA
I
Yes
Drug-induced
systemic
lupus
emythemato
sus

Discoid
erythematou
s lesions,
aphthous
lesions, ANA
positive, anti-
ds-DNA
positive

Hands,
face,
scalp

20.0
No MTX
Yes
Topical
and
systemic

Recovery, no
rechallenge

6
68
m
RA
I
Yes
Transient
swelling of
unknown
cause

Transient
swelling 2 ×
3 cm

Scalp
20.0
No MTX, folic
acid,
naproxen

No
None
Recovery

7
52
f
RA
L
Yes
Dermatomyosit
is

Livid erythema,
raised CPK,
decreased
proximal
muscular
strength

Inner upper
arms and
legs

2.5
Yes None
Yes
None
Recovery

8
53
m
RA
L
No
Erythema
nodosum

Painful
erythematou
s nodules

Lower legs 7.4
Yes AZA,
naproxen,
paracetamol

No
Topical
Partial
recovery

a A, adalimumab; I, infliximab; E, etanercept; L, lenercept. b MTX, methotrexate; AZA, azathioprine. CPK, creatinine phosphokinase; f, female, m, male.

Competing interestsThe author(s) declare that they have no competing interests.Authors' contributionsMF participated in the study design, carried out the data collection and statistical analysis, and drafted the manuscript. WV participated in the study design, carried out the data collection, and helped to write the manuscript. MC participated in the study design and coordination and helped in the writing and revision of manuscript. EdJ participated in the study design and the data collection and helped to write the manu-script. PvdK and PvR helped to write and critically revise the manuscript and gave final approval of the manuscript. MF and WV contributed equally to the article. All authors read and approved the final manuscript.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. P E Lipsky, D M Van Der Heijde, St Clair, E W Furst, D E Breedveld, F C Kalden, J R Smolen, J S Weisman, M Emery, P Feldmann, M , N Engl J Med. 343Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. L W Moreland, M H Schiff, S W Baumgartner, E A Tindall, R M Fleischmann, K J Bulpitt, A L Weaver, E C Keystone, D E Furst, P J Mease, Ann Intern Med. 130Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleis- chmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478-486.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. M E Weinblatt, E C Keystone, D E Furst, L W Moreland, M H Weisman, C A Birbara, L A Teoh, S A Fischkoff, E K Chartash, Arthritis Rheum. 48Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimu- mab, a fully human anti-tumor necrosis factor alpha mono- clonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.

Long-term efficacy and safety of etanercept in children with polyarticularcourse juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. D J Lovell, E H Giannini, A Reiff, O Y Jones, R Schneider, J C Olson, L D Stein, A Gedalia, N T Ilowite, C A Wallace, Arthritis Rheum. 48Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, et al.: Long-term efficacy and safety of etanercept in children with polyarticular- course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003, 48:218-226.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. J Brandt, A Khariouzov, J Listing, H Haibel, H Sorensen, L Grassnickel, M Rudwaleit, J Sieper, J Braun, Arthritis Rheum. 48Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grass- nickel L, Rudwaleit M, Sieper J, Braun J: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667-1675.

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. J Braun, J Brandt, J Listing, A Zink, R Alten, W Golder, E Gromnica-Ihle, H Kellner, A Krause, M Schneider, Lancet. 359Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica- Ihle E, Kellner H, Krause A, Schneider M, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. P J Mease, B S Goffe, J Metz, A Vanderstoep, B Finck, D J Burge, Lancet. 356Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. R Maini, E W St Clair, F Breedveld, D Furst, J Kalden, M Weisman, J Smolen, P Emery, G Harriman, M Feldmann, Lancet. 354Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal anti- body) versus placebo in rheumatoid arthritis patients receiv- ing concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. E C Keystone, A F Kavanaugh, J T Sharp, H Tannenbaum, Y Hua, L S Teoh, S A Fischkoff, E K Chartash, Arthritis Rheum. 50Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant meth- otrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.

Etanercept-induced subacute cutaneous lupus erythematosus. G S Bleumink, E J Borg, C G Ramselaar, Bhc Stricker, Rheumatology. 40Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHC: Etaner- cept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001, 40:1317-1319.

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. P H Brion, H A Mittal, K C Kalunian, Brion PH, Mittal HA, Kalunian KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter].

. Ann Intern Med. 131634Ann Intern Med 1999, 131:634.

Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. P D Kent, J M Davis, Mdp Davis, E L Matteson, Arthritis Rheum. 46Kent PD, Davis JM, Davis MDP, Matteson EL: Bullous skin lesions following infliximab infusion in a patient with rheuma- toid arthritis. Arthritis Rheum 2002, 46:2257-2258.

Dermatological complications of etanercept therapy for rheumatoid arthritis. L Misery, J L Perrot, P A Gentil, P B Pallot, F Cambazard, C Alexandre, Br J Dermatol. 146Misery L, Perrot JL, Gentil PA, Pallot PB, Cambazard F, Alexandre C: Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002, 146:334-335.

Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern. G Vergara, J F Silvestre, I Betlloch, P Vela, M P Albares, J C Pascual, Arch Dermatol. 138Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC: Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002, 138:1258-1259.

Atopic dermatitis-like eruption precipitated by infliximab. R C Wright, JAm Acad Dermatol. 49Wright RC: Atopic dermatitis-like eruption precipitated by infliximab. JAm Acad Dermatol 2003, 49:160-161.

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. F C Arnett, S M Edworthy, D A Bloch, D J Mcshane, J F Fries, N S Cooper, L A Healey, S R Kaplan, M H Liang, H S Luthra, Arthritis Rheum. 31Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The Amer- ican Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. M Flendrie, M C Creemers, P M Welsing, A A Den Broeder, P L Van Riel, Ann Rheum Dis. 622SupplFlendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl 2):ii30-ii33.

Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. R Rau, O Sander, P L Van Riel, L B Van De Putte, F Hasler, M Zaug, J Kneer, A P Van Der, R M Stevens, J Rheumatol. 30Rau R, Sander O, van Riel PL, van de Putte LB, Hasler F, Zaug M, Kneer J, van der AP, Stevens RM: Intravenous human recom- binant tumor necrosis factor receptor p55-Fc IgG1 fusion pro- tein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol 2003, 30:680-690.

The Nijmegen inception cohort of early rheumatoid arthritis. Pmj Welsing, Plcm Van Riel, J Rheumatol. 31Welsing PMJ, van Riel PLCM: The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol 2004, 31:14-21.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. M L Prevoo, M A Van 't Hof, H H Kuper, M A Van Leeuwen, L B Van De Putte, P L Van Riel, Arthritis Rheum. 38Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.

Cutaneous reactions to drugs. In Fitzpatrick's Dermatology in General Medicine 5th edition. R Stern, B U Wintroub, I M Freedberg, A Eisen, K Wolff, K F Austen, L A Goldsmith, S I Katz, McGraw-HillNew YorkStern R, Wintroub BU: Cutaneous reactions to drugs. In Fitz- patrick's Dermatology in General Medicine 5th edition. Edited by: Freedberg IM, Eisen A, Wolff K, Austen KF, Goldsmith LA, Katz SI. New York: McGraw-Hill; 1999:1634-1642.

Dermatologic conditions reported in patients with rheumatoid arthritis. J L Jorizzo, J C Daniels, J Am Acad Dermatol. 8Jorizzo JL, Daniels JC: Dermatologic conditions reported in patients with rheumatoid arthritis. J Am Acad Dermatol 1983, 8:439-457.

Cutaneous manifestations of rheumatoid arthritis. W L Sibbitt, R C Williams, Int J Dermatol. 21Sibbitt WL, Williams RC: Cutaneous manifestations of rheuma- toid arthritis. Int J Dermatol 1982, 21:563-572.

Skin manifestations associated with rheumatoid arthritis. T Yamamoto, H Ohkubo, K Nishioka, J Dermatol. 22Yamamoto T, Ohkubo H, Nishioka K: Skin manifestations asso- ciated with rheumatoid arthritis. J Dermatol 1995, 22:324-329.

Prevalence of dermatophytosis in patients with rheumatoid arthritis. A Bicer, U Tursen, O B Cimen, T I Kaya, S Ozisik, G Ikizoglu, C Erdogan, Rheumatol Int. 23Bicer A, Tursen U, Cimen OB, Kaya TI, Ozisik S, Ikizoglu G, Erdogan C: Prevalence of dermatophytosis in patients with rheumatoid arthritis. Rheumatol Int 2003, 23:37-40.

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. M F Doran, C S Crowson, G R Pond, W M O'fallon, S E Gabriel, Arthritis Rheum. 46Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Fre- quency of infection in patients with rheumatoid arthritis com- pared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293.

Suspected cutaneous drug toxicity in rheumatoid arthritis -an evaluation. S M Wilkinson, A G Smith, M J Davis, D L Mattey, P T Dawes, Br J Rheumatol. 32Wilkinson SM, Smith AG, Davis MJ, Mattey DL, Dawes PT: Sus- pected cutaneous drug toxicity in rheumatoid arthritis -an evaluation. Br J Rheumatol 1993, 32:798-803.

Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. M J Van Der Veen, H A Van Der, A A Kruize, J W Bijlsma, Ann Rheum Dis. 53van der Veen MJ, van der HA, Kruize AA, Bijlsma JW: Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994, 53:224-228.

Approaches for identifying and defining environmentally associated rheumatic disorders. F W Miller, E V Hess, D J Clauw, P A Hertzman, Pincus T Silver, R M Mayes, M D Varga, J Medsger, T A Love, L A , Arthritis Rheum. 43Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA: Approaches for iden- tifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000, 43:243-249.

Infection complications associated with the use of biologic agents. B Bresnihan, G Cunnane, Rheum Dis Clin North Am. 29Bresnihan B, Cunnane G: Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003, 29:185-202.

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. J Keane, Gershon S Wise, R P Mirabile-Levens, E Kasznica, J Schwieterman, W D Siegel, J N Braun, M M , N Engl J Med. 345Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associ- ated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.

Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety. K L Hyrich, A J Silman, K D Watson, D P Symmons, Ann Rheum Dis. 63Hyrich KL, Silman AJ, Watson KD, Symmons DP: Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004, 63:1538-1543.

Infections and anti-tumor necrosis factor alpha therapy. T Ellerin, R H Rubin, M E Weinblatt, Arthritis Rheum. 48Ellerin T, Rubin RH, Weinblatt ME: Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003, 48:3013-3022.

Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Tolllike receptor 4 expression. M G Netea, T Radstake, L A Joosten, J W Van Der Meer, P Barrera, B J Kullberg, Arthritis Rheum. 48Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: associa- tion with decreased interferon-gamma production and Toll- like receptor 4 expression. Arthritis Rheum 2003, 48:1853-1857.

Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. A T Chan, V Cleeve, T J Daymond, Postgrad Med J. 78Chan AT, Cleeve V, Daymond TJ: Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002, 78:47-48.

Matteson EL: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. M Baghai, D R Osmon, D M Wolk, L E Wold, G J Haidukewych, Mayo Clin Proc. 76Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Mat- teson EL: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001, 76:653-656.

Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. B Hernandez-Cruz, M H Cardiel, A R Villa, J Alcocer-Varela, J Rheumatol. 25Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J: Devel- opment, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 1998, 25:1900-1907.

Keystone EC: Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. M J Wasserman, D A Weber, J A Guthrie, V P Bykerk, P Lee, J Rheumatol. 31Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Key- stone EC: Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relation- ship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004, 31:1912-1917.

Th2-mediated atopic disease protection in Th1-mediated rheumatoid arthritis. A D Hartung, A Bohnert, H Hackstein, A Ohly, K L Schmidt, G Bein, Clin Exp Rheumatol. 21Hartung AD, Bohnert A, Hackstein H, Ohly A, Schmidt KL, Bein G: Th2-mediated atopic disease protection in Th1-mediated rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:481-484.

Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. P Hilliquin, Y Allanore, J Coste, M Renoux, A Kahan, C J Menkes, Rheumatology. 39Hilliquin P, Allanore Y, Coste J, Renoux M, Kahan A, Menkes CJ: Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. Rheumatology 2000, 39:1020-1026.

Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. M Rudwaleit, B Andermann, R Alten, H Sorensen, J Listing, A Zink, J Sieper, J Braun, Ann Rheum Dis. 61Rudwaleit M, Andermann B, Alten R, Sorensen H, Listing J, Zink A, Sieper J, Braun J: Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 2002, 61:968-974.

Allergic manifestations in patients with rheumatoid arthritis. A R Olsson, G Wingren, T Skogh, O Svernell, J Ernerudh, APMIS. 111Olsson AR, Wingren G, Skogh T, Svernell O, Ernerudh J: Allergic manifestations in patients with rheumatoid arthritis. APMIS 2003, 111:940-944.

The immunologic basis for the treatment of psoriasis with new biologic agents. J G Krueger, J Am Acad Dermatol. 46Krueger JG: The immunologic basis for the treatment of pso- riasis with new biologic agents. J Am Acad Dermatol 2002, 46:1-23.

Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. E Carlson, N Rothfield, Arthritis Rheum. 48Carlson E, Rothfield N: Etanercept-induced lupus-like syn- drome in a patient with rheumatoid arthritis. Arthritis Rheum 2003, 48:1165-1166.

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. E Favalli, L Sinigaglia, M Varenna, C Arnoldi, 11LupusFavalli E, Sinigaglia L, Varenna M, Arnoldi C: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002, 11:753-755.

Drug-induced systemic lupus erythematosus associated with etanercept therapy. N Shakoor, M Michalska, C A Harris, J A Block, Lancet. 359Shakoor N, Michalska M, Harris CA, Block JA: Drug-induced sys- temic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359:579-580.

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. P Geborek, M Crnkic, I F Petersson, T Saxne, Ann Rheum Dis. 61Geborek P, Crnkic M, Petersson IF, Saxne T: Etanercept, inflixi- mab, and leflunomide in established rheumatoid arthritis: clin- ical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61:793-798.

Anti-tumor necrosis factor-alpha therapyinduced vasculitis: case series. S J Jarrett, G Cunnane, P G Conaghan, S J Bingham, M H Buch, M A Quinn, P Emery, J Rheumatol. 30Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P: Anti-tumor necrosis factor-alpha therapy- induced vasculitis: case series. J Rheumatol 2003, 30:2287-2291.

Etanercept and infliximab associated with cutaneous vasculitis. M E Mccain, R J Quinet, W E Davis, Rheumatology. 41McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology 2002, 41:116-117.

Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. U Chaudhari, P Romano, L D Mulcahy, L T Dooley, D G Baker, Lancet. 357Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gott- lieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001, 357:1842-1847.

A randomized trial of etanercept as monotherapy for psoriasis. A B Gottlieb, R T Matheson, N Lowe, G G Krueger, S Kang, B S Goffe, A A Gaspari, M Ling, G D Weinstein, A Nayak, Arch Dermatol. 139Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, et al.: A rand- omized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003, 139:1627-1632.

Psoriasiform eruption induced by infliximab. M M Verea, Del Pozo, J Yebra-Pimentel, M T Porta, A Fonseca, E , Ann Pharmacother. 38Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E: Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004, 38:54-57.